Dr. Heather Mitchell -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Heather Mitchell, a Internal Medicine physician based in City, AZ. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Heather Mitchell has received $15,451.48 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Heather Mitchell
- Medical Specialty: Internal Medicine
- Practice Location: City, AZ, Arizona
- NPI Number: 1974962407
- Transparency Score: 50/100
- Payment Records Span: 2026-01-29 to 2026-01-29
Payment Summary
Dr. Heather Mitchell has received a total of $15,451.48 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $15,451.48 per transaction.
- Total Payments Received: $15,451.48
- Number of Transactions: 1
- Average Payment: $15,451.48
- Transparency Score: 50/100 -- This score reflects the overall payment profile relative to peers in Internal Medicine. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Heather Mitchell's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $15,451.48 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Heather Mitchell is Consulting Fees, accounting for 100% ($15,451.48) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Heather Mitchell. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Johnson & Johnson | $15,451.48 | 1 |
Dr. Heather Mitchell has a financial relationship with Johnson & Johnson, receiving $15,451.48 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Heather Mitchell. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Kisqali -- Referenced in payment records from pharmaceutical companies to Dr. Heather Mitchell
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Heather Mitchell's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Dr. Heather Mitchell, an Internal Medicine specialist in City, AZ, has a pharmaceutical payment profile characterized by a single, significant payment. With a total of $15,451.48 from pharmaceutical companies, this amount is derived from one transaction. The sole payer identified is Johnson & Johnson, which contributed the entire $15,451.48. This payment is specifically categorized as consulting and is dated for January 29, 2026. Comparing Dr. Mitchell's payment volume to peers in Internal Medicine reveals a profile that is notably different from the norm. While many internists engage in various forms of professional relationships with pharmaceutical companies, resulting in a range of payment types and amounts, Dr. Mitchell's profile is concentrated. The average internist may receive multiple smaller payments for speaking engagements, meals, consulting, or research over a year. A single, substantial payment for consulting, especially one that is in the future, stands out. The nature of this payment, a consulting fee from Johnson & Johnson, suggests a specific engagement. Without further details on the nature of the consulting, it's difficult to definitively interpret its purpose. However, consulting arrangements can range from providing expert advice on drug development to participating in advisory boards. The fact that this is the only recorded payment and it is a substantial amount for consulting warrants a closer look, though it does not automatically imply impropriety. For patients, understanding these payments is crucial for maintaining an informed perspective on their healthcare. Pharmaceutical companies invest in relationships with physicians to promote their products, educate healthcare professionals, and gather insights. While these relationships can facilitate the dissemination of valuable medical information and support research, they also carry the potential for influencing prescribing habits. Patients should be aware that even seemingly small payments can create unconscious biases. Therefore, it is important for patients to engage in open dialogue with their doctors about treatment options, understand the rationale behind prescribed medications, and consider whether alternative treatments might be suitable. In summary, Dr. Mitchell's payment profile is dominated by a single, future consulting payment from Johnson & Johnson. This deviates from the more distributed payment patterns often seen among internists. While this single payment doesn't inherently signal a problem, it does represent a significant financial relationship that patients may wish to discuss with their physician to ensure all treatment decisions are made with their best interests as the primary focus.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Heather Mitchell is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When considering your doctor's relationships with pharmaceutical companies, it's helpful to approach the information with a balanced perspective. Most doctors engage in some form of professional interaction with drug manufacturers, which can include receiving payments for consulting, speaking, or participating in research. These interactions can be a normal part of staying updated on new treatments and technologies. However, it's also important to be aware of potential influences. At your next appointment, consider asking your doctor about their relationships with pharmaceutical companies, particularly if they are prescribing a new medication. You might ask, "Are there any alternative treatments or generics available for this medication?" or "What are the pros and cons of this medication compared to others on the market?" Red flags might include a doctor who seems overly enthusiastic about a particular drug without a clear clinical rationale, or who dismisses your questions about alternatives. It's normal for doctors to have professional relationships with drug companies, especially if they are involved in research or are key opinion leaders in their field. However, if a doctor's prescribing patterns seem heavily skewed towards newer, more expensive brand-name drugs, especially from companies they receive significant payments from, it might warrant further consideration. Always prioritize open communication and trust your instincts. If you feel uncomfortable or that your concerns are not being adequately addressed, it is always your right to seek a second opinion or consider a different physician.
Peer Comparison: How Dr. Heather Mitchell Compares to Other Internal Medicine Physicians
The average Internal Medicine physician may receive several thousand dollars annually across various payment types like speaking fees, consulting, and meals. Some may receive significantly more through research grants or extensive consulting roles. Dr. Mitchell's total payment of $15,451.48, derived from a single consulting engagement, places her outside the typical pattern of multiple, smaller transactions. While the total amount might be higher than some peers, the singular nature of the payment is the most distinguishing factor.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Heather Mitchell in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Johnson & Johnson | $15,451.48 | consulting | Kisqali | 2026-01-29 | Not Assessed |
Frequently Asked Questions About Dr. Heather Mitchell's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
Is Dr. Heather Mitchell taking too much pharma money?
Dr. Mitchell has received a single payment of $15,451.48 from Johnson & Johnson for consulting, scheduled for 2026. Compared to the average internist who might receive multiple smaller payments, this profile is concentrated. While the amount is substantial for a single transaction, it's difficult to definitively label it 'too much' without understanding the context of the consulting work and comparing it to the volume and nature of consulting performed by other specialists in Internal Medicine. The key is the singular nature of this significant payment.
What pharma companies pay Dr. Heather Mitchell?
Dr. Heather Mitchell receives payments exclusively from Johnson & Johnson. The total amount from this company is $15,451.48, which represents her entire reported pharmaceutical payment history.
Should I switch doctors because of pharma payments?
Switching doctors solely based on pharmaceutical payments is a significant decision. It's more productive to first understand the nature and extent of these payments. If your doctor has a history of receiving substantial payments, especially for activities that might influence prescribing, it's reasonable to have a conversation. If you feel your doctor is not transparent, dismisses your concerns about medication costs or alternatives, or seems overly focused on specific drugs, then considering a second opinion or a new physician might be appropriate. Trust and open communication are paramount.
What kinds of payments does this doctor receive?
Dr. Mitchell's reported payments consist solely of consulting fees. The total amount of $15,451.48 is attributed to a single consulting engagement with Johnson & Johnson, scheduled for January 29, 2026. There are no reported payments for speaking, meals, travel, research, or ownership interests.
How do these payments compare to other Internal Medicine?
The average Internal Medicine physician may receive payments from multiple sources and for various activities, such as speaking, consulting, and meals, often totaling several thousand dollars annually. Dr. Mitchell's profile is distinct due to the single, substantial consulting payment from Johnson & Johnson. While the total amount might be comparable to or higher than some peers, the concentration in one payment from one company is a notable difference from the more typical, distributed payment patterns.
Do pharma payments affect prescribing quality?
Research suggests that even small financial incentives from pharmaceutical companies can influence physician prescribing habits, often unconsciously. Studies have shown correlations between receiving payments and prescribing more brand-name drugs or drugs from the paying company. However, this does not automatically mean prescribing quality is compromised. Many physicians maintain high standards of care. Patients should focus on open communication with their doctor about treatment options and rationale, rather than solely relying on payment data to judge quality.
How can I verify this payment data?
You can verify this payment data directly through the Centers for Medicare & Medicaid Services (CMS) Open Payments database. Visit the official CMS Open Payments website and use the search function to look up physicians by name and National Provider Identifier (NPI). The database provides detailed records of payments made by pharmaceutical and medical device companies to healthcare providers, including amounts, dates, and the nature of the payment.
Understanding This Doctor Payment Report
This transparency report for Dr. Heather Mitchell is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Internal Medicine physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Heather Mitchell's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Heather Mitchell and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Internal Medicine Specialty Payment Data -- See payment patterns for all internal medicine physicians
- Arizona Physician Payments -- Browse pharmaceutical payments to physicians in Arizona
- Internal Medicine Physicians in Arizona -- Compare Dr. Heather Mitchell to peers in the same state and specialty
- Johnson & Johnson Payment Profile -- View all payments made by Dr. Heather Mitchell's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Heather Mitchell's NPI (1974962407) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.